Arbutus Biopharma Corporation (NASDAQ:ABUS) Files An 8-K Entry into a Material Definitive AgreementItem 1.01 of Form 8-K.
Arbutus Biopharma Corporation (NASDAQ:ABUS) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.
On March 16, 2017, the Registrant announced that it has licensed its proprietary lipid nanoparticle (LNP) technology to Alexion, for exclusive use in one of Alexion’s rare disease programs.
Under the terms of the License Agreement, Alexion will pay the Registrant $7.5 million upfront, and payments of up to $75 million for achievement of development, regulatory, and commercial milestones, as well as single digit royalties. In addition, the Registrant will conduct technology development and provide manufacturing and regulatory support for the rapid advancement of Alexion’s mRNA product candidate.
The foregoing description of the License Agreement is not complete and is qualified in its entirety by reference to the full text of the License Agreement, which will be listed as an exhibit to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016.
The Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
Exhibit 99.1. Press release dated March 16, 2017
About Arbutus Biopharma Corporation (NASDAQ:ABUS)
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company’s lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists. Arbutus Biopharma Corporation (NASDAQ:ABUS) Recent Trading Information
Arbutus Biopharma Corporation (NASDAQ:ABUS) closed its last trading session down -0.10 at 3.30 with 3,194,234 shares trading hands.
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company’s lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists. Arbutus Biopharma Corporation (NASDAQ:ABUS) Recent Trading Information
Arbutus Biopharma Corporation (NASDAQ:ABUS) closed its last trading session down -0.10 at 3.30 with 3,194,234 shares trading hands.